Skip to main content
Immuron Ltd logo

Immuron Ltd — Investor Relations & Filings

Ticker · IMRN ISIN · US45254U1016 LEI · 529900ZIDI5C9C9TTI91 ASX Manufacturing
Filings indexed 1,602 across all filing types
Latest filing 2019-05-23 Regulatory Filings
Country AU Australia
Listing ASX IMRN

About Immuron Ltd

https://www.immuron.com.au

Immuron Ltd. is a clinical and commercial-stage biopharmaceutical company focused on developing and commercializing a novel class of orally delivered, specifically targeted polyclonal antibodies. The company's proprietary technology platform is based on polyclonal immunoglobulins (IgG) derived from hyper-immune bovine colostrum to address unmet medical needs, primarily related to gastrointestinal and enteric diseases. Its commercialized products include Travelan®, for reducing the risk of travelers' diarrhea, Protectyn®, for supporting gut and liver function, and ProIBS®, for relieving symptoms of Irritable Bowel Syndrome. Immuron's clinical pipeline includes therapeutic candidates for infectious diseases such as Clostridioides Difficile and Vancomycin-Resistant Enterococci.

Recent filings

Filing Released Lang Actions
Preliminary Prospectus Supplement filed with SEC 63 pages 554.6KB
Regulatory Filings
2019-05-23 English
Underwritten Public Offer 1 page 85.0KB
Regulatory Filings
2019-05-23 English
6-K
Foreign Filer Report
2019-05-17 English
Immuron Corporate Presentation May 2019 28 pages 1.3MB
Regulatory Filings
2019-05-16 English
Becoming a substantial holder 57 pages 1.8MB
Regulatory Filings
2019-05-07 English
FORM 6-K
Foreign Filer Report
2019-04-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.